Advion BioSystems Announces the Acquisition of NanoTek
News Aug 17, 2007
Advion BioSciences, Inc. announces that its Advion BioSystems division has completed the acquisition of NanoTek, LLC. The addition of NanoTek to Advion’s micro and nano-scale LC-MS analytical platform enables the combined companies to assume a leadership position in micro-fluidic chemistry solutions.
Advion intends to provide a complete chemistry and analytics approach for imaging diagnostics, drug discovery and biomarker research. Prior to the acquisition, Advion had been the global distribution and support partner for NanoTek.
Joe Matteo, co-founder and CEO of NanoTek, will remain with Advion and serve as President of Advion’s Accelerated Chemistry Division, based in Knoxville,TN, and become a member of Advion’s Executive Committee. Advion plans to make significant investment in NanoTek R&D and chemistry development under Mr. Matteo’s leadership.
“This acquisition is extremely strategic for the company and accretive to earnings from day one. There are numerous synergies between the companies which became obvious to us as soon as we began the initial commercial partnership. We intend to rapidly accelerate the NanoTek global commercialization and extend the product lines into pre-existing demand areas” says David B. Patteson, CEO of Advion BioSciences, Inc.
“The acquisition is all about natural partnerships and very large opportunities” adds Joe Matteo. “We see the market potential in the same way, there are many ways to integrate our product lines and the customers embrace our combined vision. We could not have found a better partner, and this is a very strategic combination.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.